Last reviewed · How we verify

Salbutamol (Ventolin®)

Khyber Teaching Hospital · FDA-approved active Small molecule ✓ Verified May 2026

Salbutamol (Ventolin®) is a Short-acting beta-2 adrenergic agonist (SABA) Small molecule drug developed by Khyber Teaching Hospital. It is currently FDA-approved for Acute bronchospasm and reversible airway obstruction in asthma, Chronic obstructive pulmonary disease (COPD) with reversible airway obstruction, Prevention of exercise-induced bronchospasm. Also known as: Group A patients: Salbutamol (Ventolin®)., Albuterol.

Salbutamol is a beta-2 adrenergic agonist that binds to beta-2 receptors on airway smooth muscle, causing relaxation and bronchodilation.

Salbutamol (Ventolin) is used to treat conditions such as Chronic Obstructive Pulmonary Disease, Pulmonary Disease, Chronic Obstructive, Asthma, and Bronchial Asthma. Its mechanism of action involves bronchodilation, although the specific details of its mechanism are not provided in the given facts.

At a glance

Generic nameSalbutamol (Ventolin®)
Also known asGroup A patients: Salbutamol (Ventolin®)., Albuterol
SponsorKhyber Teaching Hospital
Drug classShort-acting beta-2 adrenergic agonist (SABA)
TargetBeta-2 adrenergic receptor (ADRB2)
ModalitySmall molecule
Therapeutic areaRespiratory
PhaseFDA-approved

Mechanism of action

Salbutamol activates beta-2 adrenergic receptors on bronchial smooth muscle cells, triggering a cascade that increases intracellular cAMP levels. This leads to smooth muscle relaxation and rapid airway dilation, relieving bronchoconstriction. It is a short-acting beta-2 agonist (SABA) used for acute relief of airway obstruction.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Salbutamol (Ventolin®)

What is Salbutamol (Ventolin®)?

Salbutamol (Ventolin®) is a Short-acting beta-2 adrenergic agonist (SABA) drug developed by Khyber Teaching Hospital, indicated for Acute bronchospasm and reversible airway obstruction in asthma, Chronic obstructive pulmonary disease (COPD) with reversible airway obstruction, Prevention of exercise-induced bronchospasm.

How does Salbutamol (Ventolin®) work?

Salbutamol is a beta-2 adrenergic agonist that binds to beta-2 receptors on airway smooth muscle, causing relaxation and bronchodilation.

What is Salbutamol (Ventolin®) used for?

Salbutamol (Ventolin®) is indicated for Acute bronchospasm and reversible airway obstruction in asthma, Chronic obstructive pulmonary disease (COPD) with reversible airway obstruction, Prevention of exercise-induced bronchospasm.

Who makes Salbutamol (Ventolin®)?

Salbutamol (Ventolin®) is developed and marketed by Khyber Teaching Hospital (see full Khyber Teaching Hospital pipeline at /company/khyber-teaching-hospital).

Is Salbutamol (Ventolin®) also known as anything else?

Salbutamol (Ventolin®) is also known as Group A patients: Salbutamol (Ventolin®)., Albuterol.

What drug class is Salbutamol (Ventolin®) in?

Salbutamol (Ventolin®) belongs to the Short-acting beta-2 adrenergic agonist (SABA) class. See all Short-acting beta-2 adrenergic agonist (SABA) drugs at /class/short-acting-beta-2-adrenergic-agonist-saba.

What development phase is Salbutamol (Ventolin®) in?

Salbutamol (Ventolin®) is FDA-approved (marketed).

What are the side effects of Salbutamol (Ventolin®)?

Common side effects of Salbutamol (Ventolin®) include Tremor (fine hand tremor), Headache, Nervousness or anxiety, Palpitations, Muscle cramps, Tachycardia.

What does Salbutamol (Ventolin®) target?

Salbutamol (Ventolin®) targets Beta-2 adrenergic receptor (ADRB2) and is a Short-acting beta-2 adrenergic agonist (SABA).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing